{"filing":{"accession_number":"0001193125-26-305418","cik":"0001980845","ticker":"ENGNW","company_name":"enGene Therapeutics Inc.","form":"8-K","filing_date":"2026-07-16","report_date":null,"primary_document":"engn-20260715.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1980845/000119312526305418/engn-20260715.htm"},"events":[{"id":18301,"run_id":16449,"accession_number":"0001193125-26-305418","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"Dr. Richard Glickman resigned as director and chairman of the Board effective immediately on July 15, 2026, after serving in that role for over 14 years. Michael Heffernan assumes the chairman role.","company_name":"enGene Therapeutics Inc.","ticker":"ENGNW","filing_date":"2026-07-16","form":"8-K","submitted_at":null,"items":[{"id":17068,"accession_number":"0001193125-26-305418","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"Dr. Richard Glickman resigned as director and chairman of the Board effective immediately on July 15, 2026, after serving in that role for over 14 years. While the filing also discloses that Michael Heffernan assumes the chairman role, the principal disclosed action centers on Glickman's departure from his leadership position. The resignation is material given his long tenure and senior governance role at a clinical-stage biotech company approaching regulatory milestones.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T12:08:42.049798+00:00","company_name":"","ticker":null,"filing_date":""},{"id":17069,"accession_number":"0001193125-26-305418","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.72,"reasoning":"The filing discloses Dr. Richard Glickman's resignation as Chairman after 14 years of service. While the press release also announces Michael Heffernan's appointment as Chairman, the principal action disclosed is Glickman's departure from a senior leadership role. The filing emphasizes his long tenure and instrumental role in the company's evolution, making his departure the salient event, though the appointment of his successor is concurrent.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T12:08:42.049798+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17068,"accession_number":"0001193125-26-305418","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"Dr. Richard Glickman resigned as director and chairman of the Board effective immediately on July 15, 2026, after serving in that role for over 14 years. While the filing also discloses that Michael Heffernan assumes the chairman role, the principal disclosed action centers on Glickman's departure from his leadership position. The resignation is material given his long tenure and senior governance role at a clinical-stage biotech company approaching regulatory milestones.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T12:08:42.049798+00:00","company_name":"enGene Therapeutics Inc.","ticker":"ENGNW","filing_date":"2026-07-16"},{"id":17069,"accession_number":"0001193125-26-305418","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.72,"reasoning":"The filing discloses Dr. Richard Glickman's resignation as Chairman after 14 years of service. While the press release also announces Michael Heffernan's appointment as Chairman, the principal action disclosed is Glickman's departure from a senior leadership role. The filing emphasizes his long tenure and instrumental role in the company's evolution, making his departure the salient event, though the appointment of his successor is concurrent.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T12:08:42.049798+00:00","company_name":"enGene Therapeutics Inc.","ticker":"ENGNW","filing_date":"2026-07-16"}]}